Anticorps > 23311 - Purified freeze-dried antibody to procollagen type III
23311 - Purified freeze-dried antibody to procollagen type III
Human skin paraffin section, IHC
species
Human
immunogen
Pro Type III collagen
Type III procollagen, synthetized by fibroblasts, is the type III collagen precursor.
Immunogen : Pro-type III collagen .
Host : Rabbit.
Polyclonal antibodies purified by chromatography.
For research only.
Purified, freeze-dried antibody in 0.1 mL vials. Reconstitute with 0.1 mL distilled water and store aliquots at -20°C.
Unreconstituted
24 months at -20°C.
Reconstituted
Before use aliquot and store at -20°C (6 months). Avoid repeated freeze/thaw cycles.
Applications
ELISA, IB/WB, SP(RIA).
Working dilutions
ELISA ≥ 1/2000 (OD = 0.5)
Optimal dilutions should be determined by the end user.
Cross-reactivity with human and bovine.
- #405i
-
IgG
3
pH
7.21
ELISA
Optimal working dilution at 1/3000 (D0:0.5).
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #405i
-
IgG
3
pH
7.21
ELISA
Optimal working dilution at 1/3000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #405k
-
IgG
3.11
pH
7.21
ELISA
Optimal working dilution at 1/5000.
IF
Optimal working dilution not tested.
IHC
Optimal working dilution not tested.
-
- #405o
-
IgG
2.6
pH
7.34
ELISA
Optimal working dilution at 1/3000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #405h
-
IgG
3.11
pH
7.21
ELISA
Optimal working dilution at 1/5000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #504d
-
IgG
2.84 mg/mL
pH
7.42
ELISA
Optimal working dilution at 1/4000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #525d
-
IgG
2.8 mg/mL
pH
7.36
ELISA
Optimal working dilution at 1/2000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #535g
-
IgG
3.16 mg/mL
pH
7.5
ELISA
Optimal working dilution at 1/3000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
Presentation
Type III procollagen, synthetized by fibroblasts, is the type III collagen precursor.
Description
Immunogen : Pro-type III collagen .
Host : Rabbit.
Polyclonal antibodies purified by chromatography.
For research only.
Format
Purified, freeze-dried antibody in 0.1 mL vials. Reconstitute with 0.1 mL distilled water and store aliquots at -20°C.
Stability
Unreconstituted
24 months at -20°C.
Reconstituted
Before use aliquot and store at -20°C (6 months). Avoid repeated freeze/thaw cycles.
Use
Applications
ELISA, IB/WB, SP(RIA).
Working dilutions
ELISA ≥ 1/2000 (OD = 0.5)
Optimal dilutions should be determined by the end user.
Specificity
Cross-reactivity with human and bovine.
Lots
- #405i
-
IgG :
3
pH :
7.21
ELISA
Optimal working dilution at 1/3000 (D0:0.5).
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #405i
-
IgG :
3
pH :
7.21
ELISA
Optimal working dilution at 1/3000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #405k
-
IgG :
3.11
pH :
7.21
ELISA
Optimal working dilution at 1/5000.
IF
Optimal working dilution not tested.
IHC
Optimal working dilution not tested.
-
- #405o
-
IgG :
2.6
pH :
7.34
ELISA
Optimal working dilution at 1/3000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #405h
-
IgG :
3.11
pH :
7.21
ELISA
Optimal working dilution at 1/5000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #504d
-
IgG :
2.84 mg/mL
pH :
7.42
ELISA
Optimal working dilution at 1/4000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #525d
-
IgG :
2.8 mg/mL
pH :
7.36
ELISA
Optimal working dilution at 1/2000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
- #535g
-
IgG :
3.16 mg/mL
pH :
7.5
ELISA
Optimal working dilution at 1/3000.
IF
Optimal working dilution not tested with our current protocol.
IHC
Optimal working dilution not tested with our current protocol.
-
References
- «Extracellular Matrix Deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat. Lab. Invest. 1997, 76, 765-778.»
Desmoulière A., Darby I., Monte Alto Costa A., Raccurt M., Tuchweber B., Sommer P., Gabbiani G. - «Fibrosing vasculitis in Wegener's granulomatosis : ultrastructural and immunohistochemical analysis of the vascular lesions. Virchows Arch. 1995, 427, 385-393.»
Gindre D., Peyrol S., Raccurt M., Sommer P., Loire. R., Grimaud J.A., Cordier J.F. - «Le dosage des macromolécules de la matrice extracellulaire reflétant le métabolisme du cartilage : Etat de la question et perspectives. Méd et Hyg. 1994, 52, 634-638.»
Uebelhart D., Hartmann D.J. - «Comparaison de 6 marqueurs sériques potentiels de la fibrose hépatique au cours de la maladie alcoolique du foie. Gastroenterol. Clin. Biol. 1993, 17, 570-577.»
Grimbert S., Trinchet J.C., Hartmann D.J., Munz C., Garnier M., Mal F., Callard P., Beaugrand M. - «Comparaison de 6 marqueurs sériques potentiels de la fibrose hépatique au cours de la maladie alcoolique du foie. Gastroenterol. Clin. Biol. 1993, 17, 570-577.»
Grimbert S., Trinchet J.C., Hartmann D.J., Munz C., Garnier M., Mal F., Callard P., Beaugrand M. - «Four markers of collagen metabolism as possible indicators of disease in the adult respiratory distress syndrome. Am. Rev. Respir. DIs. 1993, 147, 1091-1099.»
Farjanel J., Hartmann D.J., Guidet B., Luquel L., Offenstadt G. - «Serum type I collagen and N-terminal peptide of type III procollagen in patients with alcoholic liver disease: relationship to liver histology. Alcohol. Clin. Exp. Res. 1992, 16, 342-346.»
Trinchet J.C., Hartmann D.J., Pateron D., Munz-Gotheil C., Callard P., Ville G., Beaugrand M. - «Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests. J. Hepatol. 1991, 12, 139-144.»
Trinchet J.C., Hartmann D.J., Pateron D., Laarif M., Callard P., Ville G., Beaugrand M. - «Connective tissue changes in rheumatic heart disease. J. Submicrosc. Cytol. Pathol. 1991, 23, 213-220.»
Dos Santos W.L., Verney R.N., De Montclos H., Veysseyre C, Carraz M., Grimaud J.A. - «Intra-alveolar fibrosis of idiopathic bronchiolitis obliterans-organizing pneumonia: Cell-matrix patterns. Am. J. Pathol. 1990, 137, 155-170.»
Peyrol S., Cordier J.F., Grimaud J.A. - «Morphology of chronic collagen resorption : a study on the late stages of schistosomal granuloma involution. Am. J. Path. 1988, 132, 389-399.»
Andrade Z.A., Grimaud J.A. - «Distribution of the major connective matrix components of the stromal reaction in breast carcinoma. Cell. Mol. Biol. 1987, 33, 453-467.»
Mahfouz S.M., Chevallier M., Grimaud J.A. - «The interstitial matrix of human carcinomas and sarcomas transplanted to the nude mouse : immunolocalization of some human and murine components. Cell. Mol. Biol. 1987, 33, 647-654.»
Duprez A., Guerret S., Vignaud J.M., Plenat F., Hartmann D.J., Grimaud J.A. - «Myofibroblastic stromal reaction in carcinoma of the breast : variations of collagenous matrix and structural glycoproteins. Virchows Arch. 1985, 408, 49-59.»
Lagacé R., Grimaud J.A., Schürch W., Seemayer T.A. - «A procedure for light and electron microscopic intracellular immunolocalization of collagen and fibronectin in rat liver. J. Histochem. Cytochem. 1985, 33, 407-414.»
Clement B., Rissel M., Peyrol S., Mazurier Y., Grimaud J.A., Guillouzo A.